[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363109-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363109-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","breast-cancer-mortality-among-women-who-have-attended-breastscreen-norway-19962023","Breast cancer mortality among women who have attended BreastScreen Norway, 1996–2023","","Organized mammographic screening reduces breast cancer mortality, but changes in treatment, screening techniques, and adherence may modify that benefit. This retrospective cohort study compares breast cancer mortality among women invited and who attended BreastScreen Norway (“screened”) versus invited women who did not attend (“unscreened”) from 1996 to 2023. Poisson regression estimated incidence-based mortality rate ratios adjusting for age, calendar year, time since entry, and self-selection bias using Norwegian and Duffy 2002 coefficients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/breast-cancer-mortality-among-women-who-have-attended-breastscreen-norway-19962023/363109/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/breast-cancer-mortality-among-women-who-have-attended-breastscreen-norway-19962023/363109.png","ImageObject",300,407,{"name":42,"@type":43},"Terk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-09","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s main goal?","Question",{"text":63,"@type":64},"To investigate breast cancer mortality among women invited to and who attended BreastScreen Norway versus invited women who did not attend.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What time period and population were analyzed?",{"text":68,"@type":64},"Women residing in Norway were followed from January 1, 1996, to December 31, 2023, including those aged 50–69 years without breast cancer at first invitation.",{"name":70,"@type":61,"acceptedAnswer":71},"How was mortality compared between screened and unscreened women?",{"text":72,"@type":64},"Poisson regression estimated incidence-based breast cancer mortality rate ratios, adjusting for age, calendar year, time since cohort entry, and self-selection bias using correction coefficients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363109,1790231858,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Moshina etal. Breast Cancer Research (2026) 28:75 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-026-02244-5](https://doi.org/10.1186/s13058-026-02244-5)  \nRESEARCH Open Access  \nBreast cancer mortality among women who have attended BreastScreen Norway, 1996– 2023  \nNataliia Moshina1, Jonas Gjesvik2, Xavier Castells3,4,5, Marthe Larsen1, Giske Ursin6,7,8 and Solveig Hofvind 1,9*  \nAbstract  \nBackground Organized mammographic screening has been shown to reduce breast cancer mortality across numerous high-quality studies. However, advancements in treatment, changes in screening techniques and adherence might alter the mortality reduction. In this study, we used data from an organized breast cancer screening program that started 30 years ago to investigate breast cancer mortality among women who were invited and attended the program (screened) versus women who were invited, but who did not attend (unscreened) .  \nMethods This retrospective cohort study included information on invitation to and attendance in BreastScreen Norway, breast cancer diagnosis, emigration, death, and cause of death for women residing in Norway between January 1, 1996, and December 31, 2023. A total of 1,192,148 women aged 50–69 years without diagnosis of breast cancer at first invitation to screening and inclusion in the study were followed until breast cancer death, death of other causes, emigration or end of follow-up. We applied a Poisson regression model to compare incidence-based breast cancer mortality rate ratios (MRR) with 95% confidence intervals (CI) between screened and unscreened women invited to attend the program, adjusting for age, calendar year, time since cohort entry, and self-selection bias using correction coefficients based on Norwegian data, and a coefficient proposed by Duffy in 2002.  \nResults The screened cohort comprised 14,223,189 women-years, while the unscreened cohort accounted for 2,474,340 women-years. The crude breast cancer mortality rate was 28.2 per 100,000 women-years in the screened cohort, compared to 51.2 per 100,000 women-years in the unscreened cohort. The resulting unadjusted mortality rate ratio (MRR) was 0.55 (95% CI: 0 .52–0. 59) . After adjusting for self-selection bias, the MRR remained strongly in favor of attending screening, and varied from 0.49 (95%CI 0.46–0. 53) to 0.71 (95% CI: 0 .66–0. 76) when using self-selection bias correction coefficients derived from Norwegian data and was 0.61 (95% CI: 0 .56–0. 65) when using the coefficient provided by Duffy.  \nConclusion After 27 years of follow-up, breast cancer mortality was 30–50% lower for invited and screened women compared to invited but unscreened women in BreastScreen Norway.  \nKeywords Mortality, Breast cancer, Screening, Self-selection bias, Follow-up  \n*Correspondence: Solveig Hofvind[sshh@fhi. no](sshh@fhi. no)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nIntroduction  \nBreast cancer is the most common cancer type in women worldwide, affecting over two mil","cbCainyeZBJfw1pr","https://ap.wps.com/l/cbCainyeZBJfw1pr","pdf",1098549,"English","# Abstract\n# Introduction\n## Screening effectiveness and time trends\n## Importance of long-term follow-up\n## Self-selection bias in participation","[{\"question\":\"What is the study’s main goal?\",\"answer\":\"To investigate breast cancer mortality among women invited to and who attended BreastScreen Norway versus invited women who did not attend.\"},{\"question\":\"What time period and population were analyzed?\",\"answer\":\"Women residing in Norway were followed from January 1, 1996, to December 31, 2023, including those aged 50–69 years without breast cancer at first invitation.\"},{\"question\":\"How was mortality compared between screened and unscreened women?\",\"answer\":\"Poisson regression estimated incidence-based breast cancer mortality rate ratios, adjusting for age, calendar year, time since cohort entry, and self-selection bias using correction coefficients.\"}]","Breast cancer mortality among women who have attended BreastScreen Norway, 1996–2023 | PDF",1790150054,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/554b691328f0e67aa628a9fbdf4f66d0.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d48daa519bd90c82e140ac3facc212ad.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48b77f4a5d75eecf77d82f3be5b11406.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f089fa4987053b0b3db65cda1c4a7b7.webp",980,1306]